| 產品名稱 |
CLNH5.5 |
| 商品貨號 |
B164269 |
| Organism |
human (B cell); human (myeloma) |
| Tissue |
cervix |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
2 [Cells contain Epstein-Barr virus]
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
squamous cell carcinoma |
| Applications |
The antibody reacted with cell lines derived from carcinomas of the cervix (CaSki, HeLa), lung (T293H, Calu-1 and SK-MES-1), prostate (LnCap), vulva (A431), and melanoma (SK-MEL-28). The antibody was negative for normal fibroblasts, T lymphocytes and peripheral blood lymphocytes. The antibody may be useful in therapy and diagnosis, both in vitro and in vivo. |
| Storage Conditions |
liquid nitrogen vapor phase |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix. B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061). The antibody reacted with cell lines derived from carcinomas of the cervix (CaSki, HeLa), lung (T293H, Calu-1 and SK-MES-1), prostate (LnCap), vulva (A431), and melanoma (SK-MEL-28). |
| Clinical Data |
Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix. The antibody may be useful in therapy and diagnosis, both in vitro and in vivo. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against human cervical carcinoma |
| Cellular Products |
immunoglobulin; monoclonal antibody; against human cervical carcinoma |
| Comments |
The fusion line, CRL-8061, is reported to be EBNA positive. Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix. B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061). The antibody reacted with cell lines derived from carcinomas of the cervix (CaSki, HeLa), lung (T293H, Calu-1 and SK-MES-1), prostate (LnCap), vulva (A431), and melanoma (SK-MEL-28). The antibody was negative for normal fibroblasts, T lymphocytes and peripheral blood lymphocytes. The antibody may be useful in therapy and diagnosis, both in vitro and in vivo. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10(5) viable cells/ml. Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml. Medium Renewal: Every 2 to 3 days |
| Cryopreservation |
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Temperature: 37.0°C |
| Isotype |
IgM |
| Name of Depositor |
HH Handley, Regents of the University of California |
| Deposited As |
human (B cell); human (myeloma) |
| U.S. Patent Number |
|
| References |
Handley HH, et al. Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies. US Patent 6,051,387 dated Apr 18 2000
Handley HH, et al. Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions. US Patent 6,051,229 dated Apr 18 2000
Handley HH, et al. Human-Human CLNH5-specific antibodies. US Patent 6,090,924 dated Jul 18 2000
Glassy MC, et al. Genetically stable human hybridomas secreting tumor-reactive human monoclonal IgM. Cancer Invest. 5: 449-457, 1987. PubMed: 3501329
|
